Verrica Pharmaceuticals Inc. (1NE.F)

6,24 -0,05 (-0,80%) Ab 08:02AM CEST. Markt geöffnet.

Verrica Pharmaceuticals Inc.

44 West Gay Street
Suite 400
West Chester, PA 19380
United States
484 453 3300
https://www.verrica.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 100

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Ted White	President, CEO & Director	849,21k	N/A	1965
Mr. Christopher G. Hayes	Chief Legal Officer, Secretary, Chief Compliance Officer & General Counsel	563,9k	N/A	1964
Mr. Joe Bonaccorso	Chief Commercial Officer	589,9k	N/A	1964
Mr. P. Terence Kohler	Chief Financial Officer	N/A	N/A	N/A
Dr. Gary Goldenberg M.D.	Chief Medical Officer	513,45k	N/A	1977
Mr. Eugene Scavola	Executive Vice President of Technical Operations	N/A	N/A	N/A
Dr. Bradley J. Catalone MBA, Ph.D.	Head of Drug Development	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Corporate Governance

Verrica Pharmaceuticals Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 9. Die grundlegenden Scores sind Audit: 9, Vorstand: 10, Shareholderrechte: 8, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.